Biotech Values

[Biowatch]

>>Alnylam Pharmaceuticals of Cambridge, Mass., which is developing ways of identifying disease-causing genes, is also selling shares to investors this week, and the big money management firms that buy IPO shares "are having to be coaxed into these deals," said an investment banker whose firm is involved in the Acadia IPO. <<

Didn't Alnylam already raise a ton of money as a private company? I suspect they will be the company to watch for RNAi, although a lot of companies are jumping on that bandwagon.